Review
Copyright ©The Author(s) 2025.
World J Methodol. Sep 20, 2025; 15(3): 102709
Published online Sep 20, 2025. doi: 10.5662/wjm.v15.i3.102709
Table 4 Role of mtDNA copy number in various stages of cancer development and progression
Aspect
Role of mtDNAcn
Mechanism/impact
Examples
Cancer riskAltered mtDNAcn (increase or decrease) may predispose individuals to cancer developmentImbalance in ROS productionDecreased mtDNAcn linked to breast cancer risk
Compromised cellular energy metabolismIncreased mtDNAcn linked to lung cancer risk
Tumor initiationChanges in mtDNAcn can affect mitochondrial biogenesis and metabolic reprogrammingPromotes a shift to aerobic glycolysis (Warburg effect)Low mtDNAcn observed in colorectal cancer tissues
Increases ROS, leading to genomic instability
Tumor progressionDynamic changes in mtDNAcn support adaptation to tumor microenvironmentHigh mtDNAcn enables oxidative metabolism in hypoxic conditionsElevated mtDNAcn associated with metastatic breast cancer
Supports invasive and metastatic properties
Therapeutic resistanceAltered mtDNAcn contributes to drug resistanceHigh mtDNAcn enhances oxidative phosphorylation, reducing sensitivity to certain chemotherapiesIncreased mtDNAcn linked to resistance in lung cancer treatments
Prognostic biomarkermtDNAcn alterations can predict cancer outcomesLow mtDNAcn correlates with poor prognosis in many cancersReduced mtDNAcn in gastric cancer linked to poor survival
High mtDNAcn may predict aggressive tumor behavior
Immune evasionChanges in mtDNAcn influence immune responses within the tumor microenvironmentmtDNA release into the cytoplasm activates inflammatory pathwaysmtDNA-derived DAMPs in melanoma
Alters immune surveillance mechanisms
AngiogenesismtDNAcn modulates energy demand and oxidative stress, indirectly affecting vascular growthHigh mtDNAcn supports angiogenic signalingIncreased angiogenesis in glioblastoma with altered mtDNAcn
MetastasisAltered mtDNAcn facilitates energy supply for metastatic spreadProvides metabolic flexibility for survival in secondary sitesElevated mtDNAcn in metastatic colorectal cancer